PROPHASE LABS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.04 USD | -3.26% |
|
-1.95% | +11.50% |
| May. 09 | Earnings Flash (PRPH) PROPHASE LABS Posts Q1 Revenue $3.6M, vs. Street Est of $9.9M | MT |
| May. 09 | Transcript : ProPhase Labs, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 47.06M | Sales 2025 * | 138M | Capitalization | 99.4M |
|---|---|---|---|---|---|
| Net income 2024 * | -17M | Net income 2025 * | 11M | EV / Sales 2024 * | 2.11 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.72 x |
| P/E ratio 2024 * |
-5.64
x | P/E ratio 2025 * |
10.9
x | Employees | 113 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProPhase Labs, Inc.
More recommendations
More press releases
| 1 day | -0.57% | ||
| 1 week | +2.76% | ||
| Current month | +13.02% | ||
| 1 month | -0.95% | ||
| 3 months | +5.25% | ||
| 6 months | +19.22% | ||
| Current year | +15.27% |
1 week
4.87
5.26
1 month
4.455.62
Current year
4.377.48
1 year
4.059.94
3 years
4.0515.25
5 years
0.0016.04
10 years
0.0016.04
| Managers | Title | Age | Since |
|---|---|---|---|
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
| Chief Operating Officer | 50 | Dec. 31 | |
Robert Morse
AUD | Comptroller/Controller/Auditor | 49 | 22-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Louis Gleckel
BRD | Director/Board Member | 68 | 09-05-31 |
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
Jason Barr
BRD | Director/Board Member | 44 | 15-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 25 M€ | -1.64% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 5.04 | -3.26% | 9 234 |
| 24-05-21 | 5.21 | -0.57% | 37,513 |
| 24-05-20 | 5.24 | +4.17% | 24,833 |
| 24-05-17 | 5.03 | -1.57% | 53,904 |
| 24-05-16 | 5.11 | -0.58% | 77,617 |
Delayed Quote Nasdaq, May 21, 2024 at 04:30 pm EDT
More quotes
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.21
USD
Average target price
18.5
USD
Spread / Average Target
+255.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.27% | 99.4M | |
| -23.47% | 8.01B | |
| +67.47% | 4.3B | |
| +0.29% | 2.55B | |
| -39.22% | 2.44B | |
| -8.65% | 1.89B | |
| -17.46% | 1.59B | |
| -40.70% | 1.21B | |
| +13.38% | 1.17B | |
| +15.58% | 966M |
- Stock Market
- Equities
- PRPH Stock